EP3030659A4 - Vecteur recombinant ayant un renflement a optimisé - Google Patents

Vecteur recombinant ayant un renflement a optimisé Download PDF

Info

Publication number: EP3030659A4
Authority: EP; European Patent Office
Prior art keywords: bulge; optimized; recombinant vector; recombinant; vector
Prior art date: 2013-08-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14835030.9A

Other languages

German (de)

English (en)

Other versions

EP3030659A1 (fr

Inventor

Amy H. Lin

Harry E. Gruber

Carlos Ibanez

Douglas J. Jolly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Forte Biosciences Inc

Original Assignee

Tocagen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-05

Filing date

2014-08-05

Publication date

2017-01-11

2014-08-05 Application filed by Tocagen Inc filed Critical Tocagen Inc

2016-06-15 Publication of EP3030659A1 publication Critical patent/EP3030659A1/fr

2017-01-11 Publication of EP3030659A4 publication Critical patent/EP3030659A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP14835030.9A 2013-08-05 2014-08-05 Vecteur recombinant ayant un renflement a optimisé Withdrawn EP3030659A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361862433P	2013-08-05	2013-08-05
PCT/US2014/049831 WO2015021077A1 (fr)	2013-08-05	2014-08-05	Vecteur recombinant ayant un renflement a optimisé

Publications (2)

Publication Number	Publication Date
EP3030659A1 EP3030659A1 (fr)	2016-06-15
EP3030659A4 true EP3030659A4 (fr)	2017-01-11

Family

ID=52461883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14835030.9A Withdrawn EP3030659A4 (fr)	2013-08-05	2014-08-05	Vecteur recombinant ayant un renflement a optimisé

Country Status (6)

Country	Link
EP (1)	EP3030659A4 (fr)
JP (1)	JP2016526920A (fr)
CN (1)	CN105579581A (fr)
AU (1)	AU2014306093A1 (fr)
CA (1)	CA2920049A1 (fr)
WO (1)	WO2015021077A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201710973D0 (en)	2017-07-07	2017-08-23	Avacta Life Sciences Ltd	Scaffold proteins
WO2020068631A1 (fr)	2018-09-24	2020-04-02	Merck Sharp & Dohme Corp.	Vecteurs d'expression pour systèmes d'expression eucaryotes
BR112022002406A2 (pt)	2019-08-12	2022-07-19	Purinomia Biotech Inc	Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39
WO2021063366A1 (fr) *	2019-09-30	2021-04-08	中国科学院上海药物研究所	Médicament pour le traitement de maladies artérielles et son utilisation
TW202128775A (zh)	2019-10-16	2021-08-01	英商阿法克塔生命科學有限公司	PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
KR20230010231A (ko) *	2020-05-11	2023-01-18	아빈투스 바이오, 인코포레이티드	생체내 형질도입을 위한 벡터 및 방법
GB202101299D0 (en)	2020-06-09	2021-03-17	Avacta Life Sciences Ltd	Diagnostic polypetides and methods
US12110330B2 (en)	2021-01-29	2024-10-08	Merck Sharp & Dohme Llc	Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof
WO2022234003A1 (fr)	2021-05-07	2022-11-10	Avacta Life Sciences Limited	Polypeptides se liant à cd33 avec protéine stefin a
US20240409638A1 (en)	2021-10-07	2024-12-12	Avacta Life Sciences Limited	Serum half-life extended pd-l1 binding polypeptides
EP4413038A1 (fr)	2021-10-07	2024-08-14	Avacta Life Sciences Limited	Affimers de liaison à pd-l1
CN118354793A (zh)	2022-04-29	2024-07-16	普瑞诺生物科技公司	用于治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110020814A1 (en) *	2009-06-05	2011-01-27	Ipierian, Inc.	Methods and compositions for selection of stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4937190A (en) *	1987-10-15	1990-06-26	Wisconsin Alumni Research Foundation	Translation enhancer
US20050260568A1 (en) *	2004-04-30	2005-11-24	Min Gao	Hepatitis C virus assays
ES2709481T3 (es) *	2008-09-26	2019-04-16	Tocagen Inc	Vectores recombinantes
US8829173B2 (en) *	2008-09-26	2014-09-09	Tocagen Inc.	Recombinant vectors
CN102459616A (zh) *	2009-06-17	2012-05-16	托卡根公司	复制型逆转录病毒载体的生产细胞

2014
- 2014-08-05 EP EP14835030.9A patent/EP3030659A4/fr not_active Withdrawn
- 2014-08-05 WO PCT/US2014/049831 patent/WO2015021077A1/fr not_active Ceased
- 2014-08-05 CA CA2920049A patent/CA2920049A1/fr not_active Abandoned
- 2014-08-05 CN CN201480053358.9A patent/CN105579581A/zh active Pending
- 2014-08-05 JP JP2016533383A patent/JP2016526920A/ja active Pending
- 2014-08-05 AU AU2014306093A patent/AU2014306093A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110020814A1 (en) *	2009-06-05	2011-01-27	Ipierian, Inc.	Methods and compositions for selection of stem cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMY H. LIN ET AL: "Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene", HUMAN GENE THERAPY METHODS, vol. 27, no. 2, 1 April 2016 (2016-04-01), pages 59 - 70, XP055324819, ISSN: 1946-6536, DOI: 10.1089/hgtb.2015.131 *
HOFFMAN M A ET AL: "Mutational analysis of the J-K stem-loop region of the encephalomyocarditis virus IRES", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 69, no. 7, 1 January 1995 (1995-01-01), pages 4399 - 4406, XP002450173, ISSN: 0022-538X *
HOFFMAN MICHAEL A ET AL: "Revertant analysis of J-K mutations in the encephalomyocarditis virus internal ribosomal entry site detects an altered leader protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 9, 1 January 1996 (1996-01-01), pages 6425 - 6430, XP002450175, ISSN: 0022-538X *
See also references of WO2015021077A1 *

Also Published As

Publication number	Publication date
CA2920049A1 (fr)	2015-02-12
CN105579581A (zh)	2016-05-11
WO2015021077A1 (fr)	2015-02-12
AU2014306093A2 (en)	2016-04-21
EP3030659A1 (fr)	2016-06-15
JP2016526920A (ja)	2016-09-08
AU2014306093A1 (en)	2016-03-17

Publication	Publication Date	Title
EP2979537A4 (fr)	2017-03-15	Moissonneuse-batteuse
IL241340B (en)	2022-02-01	precursor component
EP3030659A4 (fr)	2017-01-11	Vecteur recombinant ayant un renflement a optimisé
EP3036004A4 (fr)	2017-05-17	Complexe dendrimère-resvératrol
EP3063168A4 (fr)	2017-03-22	Peptides neuroprotecteurs
EP3083227A4 (fr)	2017-06-28	Construction à caractéristiques de raidissage
ZA201600729B (en)	2019-12-18	Peptides
EP3046929A4 (fr)	2017-02-08	Nouveaux peptides d'erk et leurs utilisations
IL239870A0 (en)	2015-08-31	peptide
EP3061771A4 (fr)	2017-08-16	Nouveau peptide à quatre épitopes ctl
EP3088520A4 (fr)	2017-07-26	ß-FRUCTOFURANOSIDASE AMÉLIORÉE
GB201304973D0 (en)	2013-05-01	Recombinant protein
IL239871A0 (en)	2015-08-31	peptide
EP3063278A4 (fr)	2017-04-12	Production de vecteur viral
EP2946998A4 (fr)	2017-01-25	Navire
GB201315130D0 (en)	2013-10-09	Peptides
HK1230627A1 (en)	2017-12-08	Viral peptides
AU2013904272A0 (en)	2013-11-21	Recombinant Virus
AU2013901356A0 (en)	2013-05-09	Improved Recombinant Viruses
AU2013903886A0 (en)	2013-10-24	Orientation assembly
AU2013904242A0 (en)	2013-11-21	Viral vector manufacture
GB201300529D0 (en)	2013-02-27	Recombinant polypeptide
AU2013903985A0 (en)	2013-10-31	Viral vector manufacture
AU2013904197A0 (en)	2013-11-14	Neuroprotective peptides
HUP1300040A2 (en)	2014-07-28	Gluten-free flourmix

Legal Events

Date	Code	Title	Description
2016-05-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-06-15	17P	Request for examination filed	Effective date: 20160301
2016-06-15	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-06-15	AX	Request for extension of the european patent	Extension state: BA ME
2016-11-09	DAX	Request for extension of the european patent (deleted)
2017-01-11	A4	Supplementary search report drawn up and despatched	Effective date: 20161209
2017-01-11	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/113 20100101AFI20161205BHEP
2019-01-23	17Q	First examination report despatched	Effective date: 20181219
2019-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-10-02	18D	Application deemed to be withdrawn	Effective date: 20190430